Dual Integrin αvβ3 and GRPR Targeting PET Imaging in Breast Cancer Patients

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-BBN-RGD in breast cancer patients. A single dose of 111-148 Mega-Becquerel (MBq) 68Ga-NOTA-BBN-RGD will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Peking Union Medical College Hospital
• Collaborator: National Institute for Biomedical Imaging and Bioengineering (NIBIB)

Criteria

Inclusion Criteria:

• Neoplasm identified by X-ray, ultrasound or MRI as breast cancer

• To provide basic information and sign the written informed consent.

Exclusion Criteria:

• Consisted of conditions of mental illness;

• Severe liver or kidney disease with serum creatinine > 3.0 mg/dl (270 μΜ) or any hepatic enzyme level 5 times or more than normal upper limit;

• Severe allergy or hypersensitivity to IV radiographic contrast

• Claustrophobia to accept the PET/CT scanning

• Pregnancy or breast feeding